RecruitingPhase 2NCT06316960

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Studying Chronic bilirubin encephalopathy

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Children's Hospital of Soochow University
Principal Investigator: Shaoyan Hu, MD, PhD
Children 's Hospital of Soochow University
Intervention: Avapritinib(drug)
Enrollment: 50 target
Eligibility: 18 years · All sexes
Timeline: 2024 – 2027

Study locations (12)

First Affiliated Hospital Of University of Science and Technology of China, Hefei, Anhui, China
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
Guangzhou Women and Children Medical Center, Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Kaifeng Children's Hospital, Kaifeng, Henan, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Third Xiangya Hospital of Central South University, Changsha, Hunan, China
XiangYa Hospital Central South University, Changsha, Hunan, China
Children's Hospital of Soochow University, Suzhou, Jiangsu, China
Xuzhou Children's Hospital, Xuzhou, Jiangsu, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
Children's Hospital Of Fudan University, Shanghai, Shanghai Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06316960 on ClinicalTrials.gov

Other trials for Chronic bilirubin encephalopathy

Additional recruiting or active studies for the same condition.

See all trials for Chronic bilirubin encephalopathy →

← Back to all trials